Possible contribution of β-glucosidase and caspases in the cytotoxicity of glufosfamide in colon cancer cells

European Journal of Pharmacology

Volumn 616, Issue 1-3, 2009, Pages 58-63

  Arafa, Hossam M M ^a  

^a Al Azhar University   (Egypt)

Author keywords

glucosidase; Apoptosis; Caco 2; Caspase 3; Caspase 9; Cytotoxicity; Glufosfamide; Glycoconjugate; HT29; T84

Indexed keywords

BETA GLUCOSIDASE; CASPASE 3; CASPASE 9; ESTERASE; GLUFOSFAMIDE; GLYCOCONJUGATE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN CACO 2; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-GLUCOSIDASE; CASPASE 3; CASPASE 9; CASPASES; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; PHOSPHORAMIDE MUSTARDS;

EID: 67651108804     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.06.024     Document Type: Article

References (38)

1. ADIS R&D PROFILE. Glufosfamide: Beta-D-Glc-IPM, D 19575. Drugs R. D. 6 (2005) 49-52
2. Ammons W.S., Wang J.W., Yang Z., Tidmarsh G.F., and Hoffman R.M. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia 9 (2007) 625-633
3. Becker R., Ritter A., Eichhorn U., Lips J., Bertram B., Wiessler M., Zdzienicka M.Z., and Kaina B. Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug beta-D-glucosyl-ifosfamide mustard. Br. J. Cancer 86 (2002) 130-135
4. Bradford M.M. A rapid method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Briasoulis E., Pavlidis N., Terret C., Bauer J., Fiedler W., Schöffski P., Raoul J.L., Hess D., Selvais R., Lacombe D., Bachmann P., and Fumoleau P. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-New Drug Development Group. Eur. J. Cancer 39 (2003) 2334-2340
6. Chadwick R.W., Allison J.C., Talley D.L., and George S.E. Possible errors in assay for beta-glycosidase activity. Appl. Environ. Microbiol. 61 (1995) 820-822
7. Chari R.V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41 (2008) 98-107
8. Chen C., Shen G., Hebbar V., Hu R., Owuor E.D., and Kong A.N. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis 24 (2003) 1369-1378
9. Ciuleanu T.E., Pavlovsky A.V., Bodoky G., Garin A.M., Langmuir V.K., Kroll S., and Tidmarsh G.T. A randomized Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur. J. Cancer (2009) 10.1016/j.ejca.2008.12.022
10. de Graaf M., Pinedo H.M., Quadir R., Haisma H.J., and Boven E. Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin. Biochem. Pharmacol. 65 (2003) 1875-1881
11. Denault J.B., and Salvesen G.S. Apoptotic caspase activation and activity. Methods Mol. Biol. 414 (2008) 191-220
12. Deonarain M.P., and Epenetos A.A. Targeting enzymes for cancer therapy: old enzymes in new roles. Br. J. Cancer 70 (1994) 786-794
13. Devalapally H., Navath R.S., Yenamandra V., Akkinepally R.R., and Devarakonda R.K. Beta-galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy. Arch. Pharm. Res. 30 (2007) 723-732
14. Deyev S.M., and Lebedenko E.N. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays 30 (2008) 904-918
15. Dollner R., Dietz A., Kopun M., Helbig M., Wallner F., and Granzow C. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent. Anticancer Res. 24 (2004) 2947-2951
16. Giaccone G., Smit E.F., de Jonge M., Dansin E., Briasoulis E., Ardizzoni A., Douillard J.Y., Spaeth D., Lacombe D., Baron B., Bachmann P., Fumoleau P., and EORTC-New Drug Development Group. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Eur. J. Cancer 40 (2004) 667-672
17. Guan H., McGuire M.J., Li S., and Brown K.C. Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers. Bioconjug. Chem. 19 (2008) 1813-1821
18. Gupta Y., Kohli D.V., and Jain S.K. Vitamin B12-mediated transport: a potential tool for tumor targeting of antineoplastic drugs and imaging agents. Crit. Rev. Ther. Drug Carr. Syst. 25 (2008) 347-379
19. Hannun Y. Apoptosis and the dilemma of cancer chemotherapy. Blood 89 (1997) 1845-1853
20. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
21. Ma C.L., Hsu C.L., Wu M.H., Wu C.T., Wu C.C., Lai J.J., Jou Y.S., Chen C.W., Ye S., and Chang C. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 135 (2008) 947-955
22. Mazumder S., Plesca D., and Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol. Biol. 414 (2008) 13-21
23. Mizuma T., Masubuchi S., and Awazu S. Intestinal absorption of acyclovir beta-glucoside: comparative study with acyclovir, guanosine, and kinetin beta-glucoside. Pharm. Res. 16 (1999) 69-73
24. Neuse E.W. Synthetic polymers as drug-delivery vehicles in medicine. Met. Based Drugs 2008 (2008) 1-19
25. Nicholson D.W., Ali A., and Thornberry N.A. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376 (1995) 37-43
26. Niculescu-Duvaz I. Glufosfamide Baxter Oncology. Curr. Opin. Invest. Drugs 3 (2002) 1527-1532
27. Pohl J., Bertram B., Hilgard P., Nowrousian M.R., Stüben J., and Wießler M. D-19575 - a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother. Pharmacol. 35 (1995) 364-370
28. Seker H., Bertram B., Troster H., Fisher R., Trendelenburg M., and Wiessler M. Potential influence of β-glucosidases on in vitro cytotoxicity mediated by β-D-Glc-IPM (glufosfamide), a new tumor therapeutic agent. Annu. Meet. Am. Assoc. Cancer Res. 41 (2000) 602
29. Singh Y., Palombo M., and Sinko P.J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem. 15 (2008) 1802-1826
30. Song S., Liu D., Peng J., Sun Y., Li Z., Gu J.R., and Xu Y. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm. 363 (2008) 155-161
31. Strebhardt K., and Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8 (2008) 473-480
32. Syrigos K.N., Rowlinson-Busza G., and Epenetos A.A. In vitro cytotoxicity following specific activation of amygdalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Int. J. Cancer 78 (1998) 712-719
33. van den Bent M.J., Grisold W., Frappaz D., Stupp R., Desir J.P., Lesimple T., Dittrich C., de Jonge M.J., Brandes A., Frenay M., Carpentier A.F., Chollet P., Oliveira J., Baron B., Lacombe D., Schuessler M., Fumoleau P., European Organization for Research and Treatment of Cancer New Drug Development Group, and European Organization for Research and Treatment of Cancer Brain Tumor Group and European Organization for Research and Treatment of Cancer (EORTC. Open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann. Oncol. 14 (2003) 1732-1734
34. Veyhl M., Wagner K., Volk C., Gorboulav V., Baumgarten K., Weber W.M., Schaper M., Bertram B., Wiessler M., and Koepsell H. Transport of the new chemotherapeutic agent β-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by Na-D-glucose cotransporter SAAT1. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2914-2919
35. Weichert H., Blechschmidt I., Schröder S., and Ambrosius H. The MTT-assay as a rapid test for cell proliferation and cell killing: application to human peripheral blood lymphocytes (PBL). Allerg. Immunol. (Leipz) 37 (1991) 139-144
36. Workman P. Towards intelligent anticancer drug screening in the post-genome era?. Anticancer Drug Des. 12 (1997) 525-531
37. Wu J., Lu Y., Lee A., Pan X., Yang X., Zhao X., and Lee R.J. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10 (2007) 350-357
38. Young C.D., and Anderson S.M. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res. 10 (2008) 202-210